Features of responding T cells in cancer and chronic infection

被引:249
作者
Kim, Peter S. [1 ]
Ahmed, Rafi [1 ]
机构
[1] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30322 USA
基金
美国国家卫生研究院;
关键词
ANTIGEN-SPECIFIC CD8; CHRONIC HEPATITIS-B; C VIRUS-INFECTION; CTLA-4; BLOCKADE; INFILTRATING LYMPHOCYTES; THERAPEUTIC VACCINATION; EFFECTOR FUNCTION; IN-VIVO; RESPONSES; PD-1;
D O I
10.1016/j.coi.2010.02.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ever since T cell exhaustion was initially characterized and thoroughly analyzed in the murine LCMV model, such a functional impairment has been validated in other chronic viral infections such as HIV, HCV, and HBV. In tumor immunology, it has always been postulated that tumor-reactive T cells could also become functionally exhausted owing to the high tumor-antigen load and accompanying inhibitory mechanisms. However, the empirical evidences for this hypothesis have not been as extensive as in chronic infection perhaps because much of the focus on T cell dysfunction in tumor immunology has been, and appropriately so, on breaking or bypassing immune tolerance and anergy to tumor/self antigens. On the basis of recent reports, it is becoming clear that T cell exhaustion also plays a crucial role in the impairment of antitumor immunity. In this review, we will comparatively evaluate the T cell responses in cancer and chronic infection, and the therapeutic strategies and interventions for both diseases.
引用
收藏
页码:223 / 230
页数:8
相关论文
共 73 条
[41]  
LEROUXROELS G, 2005, HUM VACCINES, P1
[42]   Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors [J].
Li, Betty ;
Van Roey, Melinda ;
Wang, Changyu ;
Chen, Tseng-Hui Timothy ;
Korman, Alan ;
Jooss, Karin .
CLINICAL CANCER RESEARCH, 2009, 15 (05) :1623-1634
[43]  
Li Q, 2007, INT J BIOL SCI, V3, P455
[44]   Long-term follow-up:: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression [J].
Lindenburg, CEA ;
Stolte, I ;
Langendam, MW ;
Miedema, F ;
Williams, IG ;
Colebunders, R ;
Weber, JN ;
Fisher, M ;
Coutinho, RA .
VACCINE, 2002, 20 (17-18) :2343-2347
[45]   Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers [J].
Mancini-Bourgine, M ;
Fontaine, H ;
Scott-Algara, D ;
Pol, S ;
Bréchot, C ;
Michel, ML .
HEPATOLOGY, 2004, 40 (04) :874-882
[46]   Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination [J].
Markowitz, M ;
Jin, X ;
Hurley, A ;
Simon, V ;
Ramratnam, B ;
Louie, M ;
Deschenes, GR ;
Ramanathan, M ;
Barsoum, S ;
Vanderhoeven, J ;
He, T ;
Chung, C ;
Murray, J ;
Perelson, AS ;
Zhang, LQ ;
Ho, DD .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (05) :634-643
[47]   CD4(+) T-CELLS ARE REQUIRED TO SUSTAIN CD8(+) CYTOTOXIC T-CELL RESPONSES DURING CHRONIC VIRAL-INFECTION [J].
MATLOUBIAN, M ;
CONCEPCION, RJ ;
AHMED, R .
JOURNAL OF VIROLOGY, 1994, 68 (12) :8056-8063
[48]   Cutting edge: Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion [J].
Mellor, AL ;
Baban, B ;
Chandler, P ;
Marshall, B ;
Jhaver, K ;
Hansen, A ;
Koni, PA ;
Iwashima, M ;
Munn, DH .
JOURNAL OF IMMUNOLOGY, 2003, 171 (04) :1652-1655
[49]   Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future [J].
Michel, ML ;
Pol, S ;
Brechot, C ;
Tiollais, P .
VACCINE, 2001, 19 (17-19) :2395-2399
[50]   Efficacy of IL-2-versus IL-15-stimulated CD8 T cells in adoptive immunotherapy [J].
Mueller, Katja ;
Schweier, Oliver ;
Pircher, Hanspeter .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (10) :2874-2885